What is CG Oncology's R&D?

CG Oncology (CGON) reported R&D of $43.73M in Q1 2026.

How has CG Oncology's R&D changed year-over-year?

CG Oncology's R&D increased by 59.2% year-over-year, from $27.47M to $43.73M.

What is the long-term trend for CG Oncology's R&D?

Over 2 years (2023 to 2025), CG Oncology's R&D has grown at a 59.7% compound annual growth rate (CAGR), from $45.75M to $116.64M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

CG Oncology CGON R&D

R&D at other companies

Cogent Biosciences, Inc.COGT

$75.37M+19.6%

Tango TherapeuticsTNGX

$33.53M-8.0%

CelcuityCELC

$33.06M+11.1%

Immunovant, Inc.IMVT

$142.29M+51.9%

Summit TherapeuticsSMMT

$132.62M+159%

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue$1.1M+1,983%

Operating income-$66.4M-57.3%

Net income-$60.2M-74.7%

EPS (diluted)-$0.71-57.8%

Balance sheet

See full

Cash & equivalents$33.7M-18.7%

Total debt$7.6M+631%

Total equity$1.1B+54.9%

Total assets$1.1B+55.9%

Cash flow

See full

Operating cash flow-$56.9M-94.5%

CapEx$304.0K+1,800%

Free cash flow-$57.2M-95.4%

Valuation

See full

Market cap$5.39B+206%

Profitability

See full

Operating margin-4,239%-1,872pp

Net margin-3,682.6%-1,601pp

FCF margin-3,163.8%-1,351pp

Returns & leverage

See full

Return on equity-20.8%+7.1pp

Debt / equity0×0.0×

Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CG Oncology's R&D?: CG Oncology (CGON) reported R&D of $43.73M in Q1 2026.
How has CG Oncology's R&D changed year-over-year?: CG Oncology's R&D increased by 59.2% year-over-year, from $27.47M to $43.73M.
What is the long-term trend for CG Oncology's R&D?: Over 2 years (2023 to 2025), CG Oncology's R&D has grown at a 59.7% compound annual growth rate (CAGR), from $45.75M to $116.64M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.